Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.4200 (-10.33%) ($9.4150 - $9.4200) on Tue. Jan. 18, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.19% (three month average) | RSI | 35 | Latest Price | $9.4200(-10.33%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | FOLD declines -8.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(61%) IWO(53%) IWC(49%) IWM(49%) XBI(48%) | Factors Impacting FOLD price | FOLD will decline at least -2.095% in a week (0% probabilities). VIXM(-30%) VXX(-13%) UUP(-13%) UNG(-8%) EDOC(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.095% (StdDev 4.19%) | Hourly BBV | -2.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-6.59(-169.96%) | Resistance Level | $11.21 | 5 Day Moving Average | $9.9(-4.85%) | 10 Day Moving Average | $10.65(-11.55%) | 20 Day Moving Average | $11.21(-15.97%) | To recent high | -24.4% | To recent low | 0% | Market Cap | $2.432b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |